A Machine to Make a Future represents a remarkably original look at the present and possible future of biotechnology research in the wake of the mapping of the human genome. The central tenet of Celera Diagnostics - the California biotech company whose formative work during 2003 is the focus of the book - is that the emergent knowledge about the genome, with its profound implications for human health, can now be turned into a powerful diagnostic apparatus - one that will yield breakthrough diagnostic and therapeutic products (and, potentially, profit). Celera's efforts - assuming they succeed - may fundamentally reshape the fabric of how health and health care are understood, practiced, and managed. Presenting a series of interviews with all of the key players in Celera Diagnostics, Paul Rabinow and Talia Dan-Cohen open a fascinating window on the complexity of corporate scientific innovation. This marks a radical departure from other books on the biotech industry by chronicling the vicissitudes of a project during a finite time period, in the words of the actors themselves. Ultimately, the authors conclude, Celera Diagnostics is engaged in a future characterized not by geniuses and their celebrated discoveries, but by a largely anonymous and widely distributed profusion of data and results - a "machine to make a future."